Cancer Type: Malignant Hematology
Study Type: Treatment
NCT#: NCT03763318
Phase: Phase I/II
Principal Investigator: Pidala, Joseph
A Phase 1B/2 Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of Eq001 In Subjects With Newly Diagnosed Acute Graft Versus Host Disease
Part A is an open label study and will enroll approximately 24 evaluable subjects with aGVHD across 4 cohorts. The total number of patients will depend on the number of dose escalations necessary to enable a decision to be made on the recommended dose to take forward into Part B of the study. The planned dose escalation will start with cohort 1, where subjects will receive EQ001 administered intravenously every two weeks for a total of 5 doses. Part B is a randomized, double-blind, placebo-controlled study and will enroll approximately 60 additional subjects, randomized in a 2:1 ratio to either active treatment EQ001 (40) or placebo (20). Subjects will receive either EQ001 or placebo administered intravenously every two weeks for a total of 5 doses.
The objectives of Part A of the study are to: Primary: *Determine the safety and tolerability of intravenous (IV) dosing of EQ001 in subjects with newly diagnosed acute graft versus host disease (aGVHD) *Determine optimal IV dose level(s) of EQ001 in subjects with newly diagnosed aGVHD Secondary: *To characterize the pharmacokinetics (PK) of EQ001 in subjects with newly diagnosed aGVHD *To characterize the pharmacodynamics (PD) of EQ001 in subjects with newly diagnosed aGVHD *To assess the PK/PD relationships of EQ001 in subjects with newly diagnosed aGVHD *To assess the clinical activity of EQ001 in subjects with newly diagnosed aGVHD The objectives of Part B of the study are to: Primary : *To define the clinical activity of EQ001 in subjects with newly diagnosed aGVHD Secondary : *To further characterize the safety, tolerability, and PD of EQ001 in subjects with newly diagnosed aGVHD
Immunotherapy
EQ001 (); Placebo ()
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub
Our patient services specialists can assist you with scheduling an appointment, questions about medical records, insurance, billing and more.
Patient Appointment Center Hours: 7 a.m. to 7 p.m. Monday - Friday; 8 a.m. to noon Saturday